Abstracts tagged "Lung Disease"

Abstract Number: 1496 • 2016 ACR/ARHP Annual Meeting
Risk for Serious Infection in Rheumatoid Arthritis Associated Interstitial Lung Disease
Alex Zamora-Legoff¹, Megan Krause², Cynthia S. Crowson³, Jay H. Ryu⁴ and Eric L. Matteson², ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN
Background/Purpose: Rheumatoid arthritis (RA) associated interstitial lung disease (ILD) carries a risk for serious infection due to lung disease, immunosuppressive therapy, and RA disease itself.…
Abstract Number: 1895 • 2016 ACR/ARHP Annual Meeting
Increased CXCL4/PF4 Presence in Systemic Sclerosis and Absence of Heparin Directed Autoantibodies
Boyang Zheng¹, Normand Blais², Jean-Luc Senécal³, Gemma Perez⁴ and Martial Koenig⁵, ¹Division of Internal Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, ²Hematology, Hôpital Notre-Dame du CHUM, Montreal, QC, Canada, ³Université de Montréal, Montréal, QC, Canada, ⁴Laboratory of autoimmunity, Centre de Recherche du CHUM, Montreal, QC, Canada, ⁵Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada
Background/Purpose: Platelet factor 4 (PF4), also called CXLC4 is a chemokine that is found in higher levels in systemic sclerosis (SSc) patients and is in…
Abstract Number: 1994 • 2016 ACR/ARHP Annual Meeting
Associations of Chronic Lung Comorbidity with Medications, Disease Activity, and All-Cause Mortality in Rheumatoid Arthritis
Bryant R. England^1,2, Harlan Sayles³, Kaleb Michaud^3,4, Liron Caplan⁵, Lisa A. Davis^6,7, Grant W. Cannon⁸, Brian Sauer⁹, E. Blair Solow¹⁰, Andreas Reimold¹¹, Gail S. Kerr¹², Pascale Schwab¹³, Joshua F. Baker¹⁴, Namrata Singh¹⁵ and Ted R. Mikuls¹⁶, ¹VA Nebraska-Western Iowa, Omaha, NE, ²Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴National Data Bank for Rheumatic Diseases, Wichita, KS, ⁵Div of Rheumatology, Denver VAMC and Univ of Colorado School of Medicine, Aurora, CO, ⁶Denver VAMC and Univ of Colorado School of Medicine, Aurora, CO, ⁷Medicine, Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO, ⁸Internal Medicine, Veterans Affairs Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ⁹IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ¹⁰Rheumatology, UT Southwestern Medical Center, Dallas, TX, ¹¹Dallas VA Medical Center and University of Texas Southwestern Medical Center, Dallas, TX, ¹²Washington DC VAMC, Georgetown University Hospital, Howard University Hospital, Washington, DC, ¹³Div Arth & Rheum Dis, Portland VA and Oregon Health & Science University, Portland, OR, ¹⁴Medicine/Rheumatology, University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ¹⁵Internal Medicine, University of Iowa Hospitals and Clinics and Iowa City VA, Iowa City, IA, ¹⁶Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: While the impact of interstitial lung disease (ILD) on mortality in RA has been demonstrated, less is known about the influence of other lung…
Abstract Number: 2071 • 2016 ACR/ARHP Annual Meeting
Expression of Neuraminidase 1 (NEU1) Is Upregulated in the Lungs of Scleroderma Patients with Pulmonary Fibrosis, and Gene Delivery of NEU1 to Mouse Lungs Elicits Accumulation of CD8+ Lymphocytes and Collagen
Irina G. Luzina^1,2, Anne E. Wyman^1,2, Virginia Lockatell², Zahid Noor², Nevins W. Todd^1,2, Simeon E. Goldblum^1,2 and Sergei P. Atamas^1,2, ¹Baltimore VA Medical Center, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: We and others have previously reported that pulmonary fibrosis in patients with scleroderma is accompanied by pulmonary accumulation of predominantly CD8+ T lymphocytes. Earlier…
Abstract Number: 1503 • 2015 ACR/ARHP Annual Meeting
A Systematic Screening of Comorbidities By the Rheumatologist in Inflammatory Rheumatisms Impacts Chronic Disease Care
Claire I. Daien¹, Amandine Tubery², Guilhem du Cailar³, Aurore Royanez⁴, Thibault Mura⁵, Marie-Christine Picot⁶, Rodolphe Bourret⁷, François Roubille⁸, Jean Bousquet⁹, Jacques Morel¹, Pierre Fesler³ and Bernard Combe¹⁰, ¹Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ²Nîmes University Hospital, Rheumatology Department, Nimes, France, ³Internal Medicine and Hypertension, Hopital Lapeyronie, Montpellier, France, ⁴Rheumatology and Pharmacology, Montpellier, France, ⁵CIC, Hopital Gui De Chauliac, Montpellier, France, ⁶DIM, Montpellier, France, ⁷Direction Teaching hospital, Montpellier, France, ⁸Cardiology, Montpellier, France, ⁹Pneumology, Montpellier, France, ¹⁰Rheumatology, Hopital Lapeyronie, Montpellier, France
Background/Purpose: Patients with inflammatory rheumatisms especially rheumatoid arthritis (RA) have a greater risk of cardiovascular diseases (CVD), infections, chronic respiratory diseases (CRD) and osteoporosis. As…
Abstract Number: 1574 • 2015 ACR/ARHP Annual Meeting
Associations of Serum Anti-Malondialdehyde-Acetaldehyde (MAA) Antibodies with Cardiovascular and Respiratory Mortality in Men with Rheumatoid Arthritis
Bryant R. England¹, Geoffrey M. Thiele², Michael J. Duryee³, Lynell Klassen⁴, Jeremy Sokolove⁵, William H. Robinson⁶, Daniel Anderson⁷, Harlan Sayles⁷, Kaleb Michaud⁸, Liron Caplan⁹, Lisa A. Davis⁹, Grant W. Cannon¹⁰, Brian Sauer¹¹, E. Blair Solow¹², Andreas Reimold¹³, Gail S. Kerr¹⁴, Pascale Schwab¹⁵, Joshua F. Baker¹⁶ and Ted R. Mikuls¹⁷, ¹Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Research Services 151, Omaha VA Medical Center, Omaha, NE, ³Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Dept of Internal Medicine, Univ of Nebraska Med Ctr, Omaha, NE, ⁵Division of Immunology and Rheumatology, Stanford University Medical Center, Mountain View, CA, ⁶Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Rheumatology & Immunology, University of Nebraska Medical Center and National Data Base for Rheumatic Diseases, Omaha, NE, ⁹Div of Rheumatology, Univ of CO Denver School of Med, Aurora, CO, ¹⁰Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ¹¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ¹²Rheumatology, UT Southwestern Medical Center, Dallas, TX, ¹³Rheumatology, VAMC, University of Texas Southwestern Medical Center, Dallas, TX, ¹⁴VAMC, Georgetown University, Washington, DC, ¹⁵Div Arth & Rheum Dis, Oregon Health & Sci Univ OP09, Portland, OR, ¹⁶Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁷Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Mortality from cardiovascular (CV) and respiratory causes is increased in rheumatoid arthritis (RA). Predictive serologic biomarkers of these events are lacking. Previously, we have…
Abstract Number: 1590 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Arthritis-Related Interstitial Lung Disease (RA-ILD): Methotrexate and the Extension of Lung Disease Are Associated to Prognosis
Jorge Rojas-Serrano¹, Denisse Herrera-Bringas², Renzo Perez-Dorame³, Mayra Mejia² and Heidegger Mateos-Toledo⁴, ¹Interstitial Lung Diseases Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, ²Interstitial Lung Diseases Unit, Insituto Nacional de Enfermedades Respiratorias, Mexico, Mexico, ³Intertitial Lung Disease Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico, ⁴Interstitial Lung Diseases Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico
Background/Purpose:Interstitial lung disease (ILD) is a severe rheumatoid arthritis manifestation with a median survival of 2.6 years. Worst survival has been associated to usual interstitial…
Abstract Number: 1612 • 2015 ACR/ARHP Annual Meeting
Association of Single Nucleotide Polymorphisms of PADI4 and HLA-DRB1 Alleles with Susceptibility to Rheumatoid Arthritis-Related Lung Diseases
Seung-Cheol Shim¹, In-Seol Yoo², Su-Jin Yoo¹, Young Kim¹, Jinhyun Kim³ and Seong-Wook Kang², ¹Rheumatology, Chungnam National University School of Medicine, Daejeon, South Korea, ²Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea, ³Internal medicine, Chungnam National University School of Medicine, Daejeon, South Korea
Background/Purpose: Lung diseases (LD) are common extra-articular manifestations in rheumatoid arthritis (RA). Recent studies have shown the association of RA-LD with anti-citrullinated protein antibodies. The…
Abstract Number: 1881 • 2015 ACR/ARHP Annual Meeting
Is the Presence of Esophageal Dilation a Poor Prognostic Factor in Dilated Interstitial Lung Disease Associated with Systemic Sclerosis?
Javier Narváez¹, Sergi Heredia², Helena Borrell Paños², Eulalia Armengol², Eugenia De Lama³ and Jose Antonio Narvaez³, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Department of Radiology. Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Several studies have shown that gastroesophageal reflux disease (GERD) is a risk factor in the progression of idiopathic pulmonary fibrosis. In systemic sclerosis (SSc),…
Abstract Number: 1889 • 2015 ACR/ARHP Annual Meeting
Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease
Natalie K. Kozij¹, John T. Granton², Philip E. Silkoff³, John Thenganatt⁴, Shobha Chakravorty⁴ and Sindhu R. Johnson⁵, ¹Department of Medicine, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada., Toronto, ON, Canada, ²Medicine, Univeristiy Health Network Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, ³Medicine, Temple University, Philadelphia, PA, ⁴Respirology, University Health Network Pulmonary Hypertension Programme, Toronto, ON, Canada, ⁵Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, Mount Sinai Hospital, Institue of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: We evaluated the ability of alveolar and conducting airway nitric oxide (NO) to discriminate between systemic sclerosis (SSc) with and without lung involvement, idiopathic…
Abstract Number: 1902 • 2015 ACR/ARHP Annual Meeting
Systemic Sclerosis and Lung Cancer Risk: Data from the Canadian Scleroderma Research Group
Lama Sakr¹, Elie Younanian², Marie Hudson³, Mianbo Wang⁴, Murray Baron⁵ and Sasha Bernatsky⁶, ¹Division of Pulmonary Diseases, Jewish General Hospital, Montreal, QC, Canada, ²Division of Pulmonary Diseases, McGill University, Montreal, QC, Canada, ³McGill University, Jewish General Hospital, Montreal, QC, Canada, ⁴Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁵Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, QC, Canada, ⁶Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: The literature supports an increased incidence of certain malignancies in patients with systemic sclerosis (SSc), including lung cancers. Predictors of lung cancer in SSc…
Abstract Number: 2600 • 2015 ACR/ARHP Annual Meeting
Signs of Immune Activation and Local Inflammation Are Present in the Bronchial Tissue of Patients with Untreated Early Rheumatoid Arthritis
Gudrun Reynisdottir^1,2, Helga Olsen³, Vijay Joshua⁴, Marianne Engström², Magnus Skold³, Anders Eklund⁵, Johan Grunewald³ and Anca I Catrina², ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ³Department of Medicine, Division of Respiratory Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ⁴Unit of Rheumatology, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁵Division of Respiratory Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Events in the lungs might contribute to generation of anti citrullinated protein antibodies (ACPA) in rheumatoid arthritis (RA). We investigated if signs of immune…
Abstract Number: 274 • 2015 ACR/ARHP Annual Meeting
Shrinking Lung Syndrome in Connective Tissue Disease
Helena Borrell Paños¹, Javier Narváez², Juan José Alegre³, Ivan Castellvi⁴, Francesca Mitjavila⁵, Eulalia Armengol¹, Joan Miquel Nolla¹ and Maria Molina⁶, ¹Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, ⁴Rheumatology Unit. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁵Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Department of Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Shrinking lung syndrome (SLS) is a rare a little known complication associated with systemic lupus erythematosus (SLE) and other connective tissue diseases (CTDs). This…
Abstract Number: 304 • 2015 ACR/ARHP Annual Meeting
Abnormal Pulmonary Function Tests, Interstitial Lung Disease, and Lung Function Decline in Patients with Classic and Clinically Amyopathic Dermatomyositis
Michael George¹, Maryl Kreider², Rupal Shah², Wallace Miller Jr.³, Peter A. Merkel⁴ and Victoria Werth^5,6, ¹Department of Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Pulmonary, Allergy & Critical Care, University of Pennsylvania, Philadelphia, PA, ³Radiology, University of Pennsylvania, Philadelphia, PA, ⁴Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵Dermatology, Veterans Affairs Medical Center, Philadelphia, PA, ⁶Dermatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Interstitial lung disease (ILD) is common in classic dermatomyositis (DM) and clinically amyopathic dermatomyositis (CADM), in which rash is present without weakness. Previous studies…
Abstract Number: 1038 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Alpha and Peptidylarginine Deiminase 4 in Lung and Joint Inflammation
Mandar Bawadekar¹, Annette Gendron-Fitzpatrick², Thomas F. Warner³, Lennart K.A. Lundblad⁴, Paul Thompson⁵ and Miriam A. Shelef^1,6, ¹Medicine, University of Wisconsin, Madison, WI, ²Comparative Pathology Laboratory of the Research Animal Resources Center and Pathobiological Sciences, University of Wisconsin, Madison, WI, ³Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, ⁴Medicine, The University of Vermont, Burlington, VT, ⁵University of Massachusetts, Worcester, MA, ⁶Medicine, William S. Middleton Memorial Veterans Hospital, Madison, WI
Background/Purpose: The relationship between lung and joint inflammation in rheumatoid arthritis is poorly understood. About 10% of people with rheumatoid arthritis develop interstitial lung disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].